Table 2. Anti-VEEV Activity of Selected Analogues.
See Table S1 for full list of analogues. Compounds 1, 2, and 9–13 were tested at concentrations of 11.43 nM–25 μM (8 doses, 3-fold dilution) whereas compounds 14–16 were tested from 22.86 nM–50 μM (8 doses, 3-fold dilution). BE(2)-M17 and Neuro-2a cells were treated with the indicated compounds and 2 h later inoculated with VEEV TC83 (MOI = 1.2 and 3.5, respectively). After 7 h, cells were fixed and stained with antibodies against E2. High-content quantitative image-based analysis was used to measure relative infection rates.
Compounds were assayed in VEEV Trinidad-infected Vero cells (MOI = 0.01).
Compounds were assayed in VEEV Trinidad-infected HeLa cells (MOI = 0.1).
Compounds were assayed in VEEV TC83-infected mouse cortical neurons (MOI = 0.04). Cells were fixed 20 h after virus inoculation and stained and analyzed as above.